Cabaletta Bio, Inc. (NASDAQ:CABA - Free Report) - Cantor Fitzgerald issued their FY2025 earnings estimates for shares of Cabaletta Bio in a note issued to investors on Tuesday, January 21st. Cantor Fitzgerald analyst J. Schimmer anticipates that the company will post earnings per share of ($2.19) for the year. The consensus estimate for Cabaletta Bio's current full-year earnings is ($2.34) per share.
A number of other equities analysts have also recently issued reports on CABA. Wells Fargo & Company cut Cabaletta Bio from an "overweight" rating to an "equal weight" rating and lowered their target price for the stock from $12.00 to $6.00 in a report on Thursday, December 19th. UBS Group started coverage on Cabaletta Bio in a research report on Thursday, October 10th. They issued a "buy" rating and a $10.00 target price on the stock. Evercore ISI downgraded shares of Cabaletta Bio from an "outperform" rating to an "inline" rating and lowered their price objective for the company from $15.00 to $6.00 in a report on Friday, December 20th. William Blair reaffirmed an "outperform" rating on shares of Cabaletta Bio in a research report on Monday, November 18th. Finally, HC Wainwright reissued a "buy" rating and set a $25.00 price target on shares of Cabaletta Bio in a research report on Friday, January 17th. One equities research analyst has rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, Cabaletta Bio currently has a consensus rating of "Buy" and a consensus target price of $24.38.
Check Out Our Latest Report on Cabaletta Bio
Shares of CABA stock opened at $2.54 on Thursday. Cabaletta Bio has a 12-month low of $1.76 and a 12-month high of $26.35. The firm has a fifty day moving average of $2.65 and a 200-day moving average of $4.30. The company has a market capitalization of $124.16 million, a price-to-earnings ratio of -1.18 and a beta of 2.46.
A number of hedge funds have recently made changes to their positions in CABA. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Cabaletta Bio in the 3rd quarter valued at $32,000. Point72 DIFC Ltd acquired a new position in Cabaletta Bio in the third quarter valued at $33,000. China Universal Asset Management Co. Ltd. boosted its position in Cabaletta Bio by 65.7% during the third quarter. China Universal Asset Management Co. Ltd. now owns 9,395 shares of the company's stock valued at $44,000 after acquiring an additional 3,724 shares during the last quarter. Intech Investment Management LLC acquired a new stake in Cabaletta Bio during the 3rd quarter worth about $67,000. Finally, Avanza Fonder AB bought a new position in shares of Cabaletta Bio in the 4th quarter worth about $40,000.
Cabaletta Bio, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Cabaletta Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cabaletta Bio wasn't on the list.
While Cabaletta Bio currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.